47 related articles for article (PubMed ID: 30215271)
1. Synthesis, molecular modeling and biological screening of some pyrazole derivatives as antileishmanial agents.
Bekhit AA; Saudi MN; Hassan AM; Fahmy SM; Ibrahim TM; Ghareeb D; El-Seidy AM; Al-Qallaf SM; Habib HJ; Bekhit AEA
Future Med Chem; 2018 Oct; 10(19):2325-2344. PubMed ID: 30215271
[TBL] [Abstract][Full Text] [Related]
2. In silico study and in vitro antileishmanial and antitrypanosomal evaluation of azopyrazoles and azopyrimidines.
Am Alkhaldi A; F Lamie P; A Abdelgawad M
Pak J Pharm Sci; 2024 Jan; 37(1(Special)):173-184. PubMed ID: 38747267
[TBL] [Abstract][Full Text] [Related]
3. Spiro-Acridine Compound as a Pteridine Reductase 1 Inhibitor: in silico Target Fishing and in vitro Studies.
de Oliveira Viana J; Sena Mendes M; Santos Castilho M; Olímpio de Moura R; Guimarães Barbosa E
ChemMedChem; 2024 Jun; 19(11):e202300545. PubMed ID: 38445815
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, antileishmanial, antimalarial evaluation and molecular docking study of some hydrazine-coupled pyrazole derivatives.
Berhe HG; Birhan YS; Beshay BY; Habib HJ; Hymete A; Bekhit AA
BMC Chem; 2024 Jan; 18(1):9. PubMed ID: 38191485
[TBL] [Abstract][Full Text] [Related]
5. Spiro heterocycles bearing piperidine moiety as potential scaffold for antileishmanial activity: synthesis, biological evaluation, and
Mohamed MAA; Kadry AM; Bekhit SA; Abourehab MAS; Amagase K; Ibrahim TM; El-Saghier AMM; Bekhit AA
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):330-342. PubMed ID: 36444862
[TBL] [Abstract][Full Text] [Related]
6. Designing Antitrypanosomal and Antileishmanial BODIPY Derivatives: A Computational and In Vitro Assessment.
Gonçalves RCR; Teixeira F; Peñalver P; Costa SPG; Morales JC; Raposo MMM
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731562
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of quinoline-piperazine/pyrrolidine derivatives as possible antileishmanial agents.
Katiyar S; Ramalingam K; Kumar A; Ansari A; Bisen AC; Mishra G; Sanap SN; Bhatta RS; Purkait B; Goyal N; Sashidhara KV
Eur J Med Chem; 2023 Dec; 261():115863. PubMed ID: 37837672
[TBL] [Abstract][Full Text] [Related]
8. Leishmanicidal activity and 4D quantitative structure-activity relationship and molecular docking studies of vanillin-containing 1,2,3-triazole derivatives.
Rodrigues Gazolla PA; Lima WP; de Aguiar AR; Gonçalves Borsodi MP; Costa AV; de Oliveira FM; de Oliveira OV; Andreazza Costa MC; Castro Ferreira MM; do Nascimento CJ; Junker J; Vaz BG; Teixeira RR
Future Med Chem; 2024 Jan; 16(2):139-155. PubMed ID: 38131191
[No Abstract] [Full Text] [Related]
9. Late-Stage Diversification of Pyrazoles as Antileishmanial Agents.
Winge T; Perry B; Matheeussen A; Caljon G; Wünsch B
ChemMedChem; 2024 Apr; 19(8):e202400028. PubMed ID: 38289147
[TBL] [Abstract][Full Text] [Related]
10. One-pot synthesis of polyhydroquinoline-1,2,3-triazole hybrids in deep eutectic solvent as anti-leishmanial agents and molecular modeling studies.
Molaei S; Farhadi G; Talezari M; Gholizadeh N; Mahnam K; Keivanloo A; Sepehri S
J Biomol Struct Dyn; 2024 Jun; 42(9):4834-4850. PubMed ID: 37325813
[TBL] [Abstract][Full Text] [Related]
11. Antileishmanial effects and drugability characteristics of a heterocyclic copper complex: An in silico, in vitro and molecular study.
Mirzaei M; Sharifi I; Mohammad-Rafi F; Anjomshoa M; Abiri A; Moqaddari AH; Nooshadokht M; Raiesi O; Amirheidari B
J Inorg Biochem; 2023 Aug; 245():112245. PubMed ID: 37167732
[TBL] [Abstract][Full Text] [Related]
12. Antileishmanial evaluation of triazole-butenolide conjugates: design, synthesis,
Pandey AR; Singh SP; Ramalingam K; Yadav K; Bisen AC; Bhatta RS; Srivastava M; Tripathi R; Goyal N; Sashidhara KV
RSC Med Chem; 2023 Jun; 14(6):1131-1142. PubMed ID: 37360388
[TBL] [Abstract][Full Text] [Related]
13. Computational studies on potential small molecule inhibitors of
Boakye A; Gasu EN; Mensah JO; Borquaye LS
J Biomol Struct Dyn; 2023; 41(21):12128-12141. PubMed ID: 36632757
[TBL] [Abstract][Full Text] [Related]
14. Inherent efficacies of pyrazole-based derivatives for cancer therapy: the interface between experiment and
Dube ZF; Soremekun OS; Ntombela T; Alahmdi MI; Abo-Dya NE; Sidhom PA; Shawky AM; Shibl MF; Ibrahim MA; Soliman ME
Future Med Chem; 2023 Sep; 15(18):1719-1738. PubMed ID: 37772542
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and evaluation of prenylated chalcones ethers as promising antileishmanial compounds.
Hernández-Rivera JL; Espinoza-Hicks JC; Chacón-Vargas KF; Carrillo-Campos J; Sánchez-Torres LE; Camacho-Dávila AA
Mol Divers; 2023 Oct; 27(5):2073-2092. PubMed ID: 36306047
[TBL] [Abstract][Full Text] [Related]
16. Screening of the antileishmanial and antiplasmodial potential of synthetic 2-arylquinoline analogs.
Espinosa-Saez R; Robledo SM; Pineda T; Murillo J; Zúñiga C; Yañez O; Cantero-López P; Saez-Vega A; Guzmán-Teran C
Sci Rep; 2023 Oct; 13(1):17523. PubMed ID: 37845281
[TBL] [Abstract][Full Text] [Related]
17. N-Pyrazolyl- and N-Triazolylamines and -Ureas as Antileishmanial and Antitrypanosomal Drugs.
Winge T; Imberg L; Perry B; Matheeussen A; Caljon G; Kalinin D; Wünsch B
ChemMedChem; 2024 Apr; ():e202400220. PubMed ID: 38687962
[TBL] [Abstract][Full Text] [Related]
18. Pteridine reductase (PTR1): initial structure-activity relationships studies of potential leishmanicidal arylindole derivatives compounds.
Silva JV; Sueyoshi S; Snape TJ; Lal S; Giarolla J
SAR QSAR Environ Res; 2023; 34(8):661-687. PubMed ID: 37606690
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Silico Evaluations of the Antileishmanial Activities of New Benzimidazole-Triazole Derivatives.
Eser M; Çavuş İ
Vet Sci; 2023 Nov; 10(11):. PubMed ID: 37999471
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Repurposing of Rosmarinic Acid-β-Amino-α-Ketoamide Hybrids as Antileishmanial Agents.
Hassan AHE; Bayoumi WA; El-Sayed SM; Phan TN; Oh T; Ham G; Mahmoud K; No JH; Lee YS
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
